Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Stomach Neoplasms

Carcinoma

Carcinoma, Squamous Cell

Esophageal Neoplasms

Adenocarcinoma

Esophageal Squamous Cell Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Stomach Cancer

Esophageal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Anlotinib Hydrochloride Combined With Nivolumab in the second line treatment of Gastric and Esophageal Cancer patients

Anlotinib Hydrochloride Combined With Nivolumab in the second line Treatment of Gastric and Esophageal Cancer patients

Anlotinib Hydrochloride With Nivolumab

Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study. In the current study, the efficacy and safety of anlotinib hydrochloride combined with nivolumab as second-line or salvage chemotherapy will be evaluated in Chinese patients with advanced gastric adenocarcinoma and esophageal squamous cell carcinoma. 48 patients could provide adequate precision rather than controlling type I\&II error.

Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer

A Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma as Second-line or Salvage Chemotherapy

The ORR in patients with unresectable or metastatic GC or ESCC patients treated with anlotinib hydrochloride in combination with nivolumab as a second-line or later treatment.

The PFS was calculated from the initiation of chemotherapy to the date of disease progression or death.

Overall survival was measured from the initiation of chemotherapy to the date of the last follow-up or death.

Shanghai Zhongshan Hospital

Doctor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer	NCT04503967	Gastric Adenoca... Esophageal Squa...	Anlotinib Hydro...	15 Years - 75 Years	Shanghai Zhongshan Hospital
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer	NCT04503967	Gastric Adenoca... Esophageal Squa...	Anlotinib Hydro...	15 Years - 75 Years	Shanghai Zhongshan Hospital

Spots Global Cancer Trial Database for anlotinib hydrochloride with nivolumab